The systemic exposure to the anticancer agent irinotecan (CPT-11) and its active metabolite SN-38 were 79 and 92% reduced, respectively, relative to literature data, by concomitant phenytoin therapy. This finding suggests that increased doses of CPT-11 should be given to patients treated simultaneously with these drugs, to achieve adequate levels of SN-38. [

, ,,
Anti-Cancer Drugs
Department of Medical Oncology

Mathijssen, R., Sparreboom, A., Dumez, H., van Oosterom, A., & de Bruijn, E. (2002). Altered irinotecan metabolism in a patient receiving phenytoin. Anti-Cancer Drugs, 13(2), 139–140. doi:10.1097/00001813-200202000-00004